Drug intelligence / Profile preview

F528

Development stage: Preclinical
Lead developer: Catalyst Biosciences
Modality: Small Molecules

Overview

F528 is a novel small molecule anti-inflammatory agent under preclinical development for the treatment of chronic obstructive pulmonary disease (COPD). It acts by inhibiting multiple inflammatory cytokines, with the potential to modify disease progression in COPD. The drug is being evaluated as a potential first-line therapy for COPD and may have broader applications in other inflammatory conditions. Development activities are primarily reported in China, and it has not yet reached clinical trial phases[1][3].

Beyond the preview

Go deeper on F528.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F528.

Explore the full profile